Company intelligence / Profile preview

EpiHealth

Charleston, South Carolina, United States

Ownership: Private
Employees: ~40
Development stage: Other

Overview

EpiHealth is a specialty pharmaceutical company dedicated to providing innovative therapeutic solutions for dermatological conditions. Based in South Carolina, the company focuses on the commercialization of prescription products for the U.S. market, targeting diseases such as plaque psoriasis, rosacea, and acne. Its commercial portfolio includes notable brands like Wynzora, Rhofade, and Minolira. Originally an independent entity, EpiHealth was acquired by Novan in 2022 to bolster its commercial infrastructure. Following Novan's bankruptcy in 2023, the assets and commercial operations of EpiHealth were transitioned under the ownership of Ligand Pharmaceuticals.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

MC2 TherapeuticsAclaris Therapeutics

Beyond the preview

Go deeper on EpiHealth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiHealth.

Explore the full profile